No new efficacy numbers were disclosed, but Celcuity will present updated subgroup and safety results from the randomized Phase 3 VIKTORIA-1 trial on December 11 at SABCS. The oral presentation covers gedatolisib, a multi-target PI3K/AKT/mTOR inhibitor, in combination with fulvestrant with or without palbociclib for second-line treatment of HR+/HER2- advanced breast cancer in the PIK3CA–wild-type population. According to the company, enrollment in VIKTORIA-1 is complete, detailed results for the wild-type cohort have previously been reported, and the PIK3CA-mutant cohort is fully enrolled.
The core news is scheduling and scope: an oral “Rapid Fire” slot indicates a dataset the meeting deemed clinically relevant, with additional subgroup efficacy analyses and safety details forthcoming. Beyond VIKTORIA-1, Celcuity is running VIKTORIA-2, a first-line Phase 3 testing gedatolisib plus a CDK4/6 inhibitor and fulvestrant, and a Phase 1/2 study combining gedatolisib with darolutamide in metastatic castration-resistant prostate cancer. The immediate focus, however, is whether the VIKTORIA-1 update substantiates a role for multi-node PAM pathway blockade post-CDK4/6 and fulvestrant in a biomarker segment not specifically addressed by PI3Kα-selective agents.
Strategically, this is a positioning move into the gap between mutation-specific therapy and endocrine-only salvage. By emphasizing PIK3CA–wild-type patients in second line, Celcuity is targeting a population for whom existing PI3Kα inhibitors are not indicated, while also testing whether comprehensive PAM inhibition can outperform single-node approaches now in market. The trial’s inclusion of a regimen that continues palbociclib beyond progression is notable. That strategy has generated mixed results across programs; if VIKTORIA-1 demonstrates a clear incremental benefit with acceptable tolerability, it would support a controversial but increasingly explored post-progression paradigm. If not, the value proposition may need to rest on gedatolisib’s performance without CDK4/6 continuation and its ability to deliver consistent benefit across endocrine-resistance phenotypes.
For sites and CROs, the operational burden will hinge on the safety profile that emerges at SABCS. Multi-target PAM inhibition often comes with metabolic and dermatologic toxicities and dose-management requirements that can slow enrollment and drive discontinuations. Clarification of monitoring intensity, dose modification rates, and discontinuation percentages will directly inform site readiness and patient throughput in both current and planned studies. For sponsors competing in HR+/HER2- post-CDK4/6, the subgroup analyses will matter: outcomes stratified by prior CDK4/6 duration, visceral disease, endocrine sensitivity, and circulating tumor DNA dynamics could shape future eligibility criteria and stratification schemas. Regulators will be looking for consistency across clinically meaningful subgroups and clean safety management, especially if Celcuity ultimately seeks a label not constrained by a single gene alteration.
The next catalyst is the SABCS readout, where the durability of benefit, hazard ratios in key subgroups, and safety-driven discontinuation rates will set the tone for regulatory dialogue. Watch for clarity on the PIK3CA-mutant cohort analysis plan and timing, and whether the company signals alignment with FDA on endpoints and population definitions that could differentiate a PIK3CA–wild-type claim. For VIKTORIA-2, any indication of enrollment velocity, interim analysis design, and risk mitigation around class-related toxicities will be a barometer for first-line ambitions. The unresolved questions are whether the efficacy delta justifies the added complexity of multi-node inhibition in routine practice and whether continuation of CDK4/6 beyond progression can earn a place in guidelines. The answers will determine if gedatolisib can carve out space in a crowded pathway and reshape post-CDK4/6 sequencing rather than becoming another incremental option.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
